Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study (Q33710034)

28 July 2017

Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study (English)

1 reference

28 July 2017

Michael A Campos

4

0 references

Kenneth Chapman

object named as

Kenneth R Chapman

5

0 references

Charlie Strange

object named as

Charlie Strange

8

0 references

author name string

James M Stocks

1

1 reference

28 July 2017

Mark L Brantly

2

1 reference

28 July 2017

Laurene Wang-Smith

3

1 reference

28 July 2017

Friedrich Kueppers

6

1 reference

28 July 2017

Robert A Sandhaus

7

1 reference

28 July 2017

Gerard Turino

9

1 reference

28 July 2017

30 September 2010

1 reference

BMC Clinical Pharmacology

28 July 2017

1 reference

28 July 2017

10

1 reference

28 July 2017

13

1 reference

https://scigraph.springernature.com/pub.10.1186/1472-6904-10-13

28 July 2017

0 references

cites work

Hereditary alpha-1-antitrypsin deficiency and its clinical consequences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958874

Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958874

Clearance of prions during plasma protein manufacture.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958874

Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958874

Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958874

Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2958874

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1472-6904-10-13

Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor

21 January 2018

1 reference

12 December 2020

Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events

1 reference

12 December 2020

Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group

1 reference

12 December 2020

Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis

1 reference

12 December 2020

Yield improvement for manufacture of alpha-proteinase inhibitor

1 reference

12 December 2020

Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1186/1472-6904-10-13

1 reference

Dimensions Publication ID

28 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1472-6904-10-13

9 September 2019

1 reference

28 July 2017

1 reference